In June 2017, the management of Cornerstone Pharmaceuticals, Inc., announced change of the corporate name to Rafael Pharmaceuticals, Inc. Signifying a new era in the companyâs evolution during which the company aims to usher in a new paradigm in anticancer treatment with its breakthrough metabolic cancer drugs, the new name is derived from Raphael, the biblical angel of healing. As Cornerstone Pharmaceuticals, Inc. the firm has been organized around discovery and development of cancer therapies. The companyâs products include EmPAC, an emulsiphan-based composition that delivers anti-mitotic agents selectively on cancer cells; altered energy metabolism directed drugs, which convert glucose to energy that is used to kill human tumor cells; and CPI-613, drug from Altered Energy Metabolism Directed (AEMD) platform, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is currently in Phase I/II clinical trials. Based in Cranbury, NJ., the firm has additional offices and laboratory facilities in Stony Brook, NY; Cornerstone Pharmaceuticals, Inc. operates as a subsidiary of Raf
